APA

Kenter G. G., Welters M. J. P., Valentijn A. R. P. M., Lowik M. J. G., Berends-van der Meer D. M. A., Vloon A. P. G., Drijfhout J. W., Wafelman A. R., Oostendorp J., Fleuren G. J., Offringa R., van der Burg S. H. & Melief C. J. M. (20080327). Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Kenter Gemma G, Welters Marij J P, Valentijn A Rob P M, Lowik Margriet J G, Berends-van der Meer Dorien M A, Vloon Annelies P G, Drijfhout Jan W, Wafelman Amon R, Oostendorp Jaap, Fleuren Gert Jan, Offringa Rienk, van der Burg Sjoerd H and Melief Cornelis J M. 20080327. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Kenter G. G., Welters M. J. P., Valentijn A. R. P. M., Lowik M. J. G., Berends-van der Meer D. M. A., Vloon A. P. G., Drijfhout J. W., Wafelman A. R., Oostendorp J., Fleuren G. J., Offringa R., van der Burg S. H. and Melief C. J. M. (20080327). Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Kenter Gemma G, Welters Marij J P, Valentijn A Rob P M, Lowik Margriet J G, Berends-van der Meer Dorien M A, Vloon Annelies P G, Drijfhout Jan W, Wafelman Amon R, Oostendorp Jaap, Fleuren Gert Jan, Offringa Rienk, van der Burg Sjoerd H and Melief Cornelis J M. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20080327.